News Image

Why the dividend investor may take a look at NYSE:PFE.

By Mill Chart

Last update: Oct 12, 2023

Our stock screener has singled out PFIZER INC (NYSE:PFE) as a promising choice for dividend investors. NYSE:PFE not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.

Analyzing Dividend Metrics

ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:PFE scores a 8 out of 10:

  • PFE has a Yearly Dividend Yield of 4.90%, which is a nice return.
  • Compared to an average industry Dividend Yield of 3.93, PFE pays a better dividend. On top of this PFE pays more dividend than 97.14% of the companies listed in the same industry.
  • PFE's Dividend Yield is rather good when compared to the S&P500 average which is at 2.76.
  • PFE has paid a dividend for at least 10 years, which is a reliable track record.
  • PFE has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

Evaluating Health: NYSE:PFE

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has achieved a 5 out of 10:

  • PFE's Altman-Z score of 2.67 is fine compared to the rest of the industry. PFE outperforms 73.33% of its industry peers.
  • Looking at the Debt to FCF ratio, with a value of 6.13, PFE belongs to the top of the industry, outperforming 84.76% of the companies in the same industry.
  • PFE has a Current Ratio of 2.12. This indicates that PFE is financially healthy and has no problem in meeting its short term obligations.

Profitability Assessment of NYSE:PFE

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:PFE, the assigned 8 is a significant indicator of profitability:

  • With an excellent Return On Assets value of 9.75%, PFE belongs to the best of the industry, outperforming 90.95% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 21.68%, PFE belongs to the top of the industry, outperforming 91.90% of the companies in the same industry.
  • PFE has a better Return On Invested Capital (11.96%) than 90.00% of its industry peers.
  • The last Return On Invested Capital (11.96%) for PFE is well below the 3 year average (16.16%), which needs to be investigated, but indicates that PFE had better years and this may not be a problem.
  • PFE's Profit Margin of 27.55% is amongst the best of the industry. PFE outperforms 94.76% of its industry peers.
  • PFE has a better Operating Margin (31.21%) than 95.71% of its industry peers.
  • In the last couple of years the Operating Margin of PFE has grown nicely.
  • Looking at the Gross Margin, with a value of 68.78%, PFE is in the better half of the industry, outperforming 74.29% of the companies in the same industry.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

For an up to date full fundamental analysis you can check the fundamental report of PFE

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

PFIZER INC

NYSE:PFE (4/26/2024, 7:09:35 PM)

Premarket: 25.53 +0.13 (+0.51%)

25.4

+0.14 (+0.55%)

PFE News

News Image43 minutes ago - InvestorPlace3 Dividend Stocks to Buy on the Dip: April 2024

With the market presenting many vagaries, investors may take some solace in these dividend stocks to buy on the dip.

News Image12 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose

Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.

News Image20 hours ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Imagea day ago - The Motley Fool3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

News Image2 days ago - The Motley Fool3 Dividend Stocks to Buy and Hold for the Next Decade

You'll get dividends and more with these great stocks.

News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now for Steady Returns in Any Market

Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.

News Image3 days ago - CNBCCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

News Image3 days ago - Market News VideoJune 7th Options Now Available For Pfizer (PFE)
News Image3 days ago - The Motley FoolWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Put your money to work by investing in these three high-quality dividend stocks.

News Image3 days ago - BloombergPfizer’s First Gene Therapy Gets Approval for Clotting Disorder

Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.

News Image3 days ago - CNBCFDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. 

News Image3 days ago - Investor's Business DailyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy

Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.

PFE Links
Follow us for more